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Systemic inflammation and metabolic disorders are among the mechanisms linking
obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients
with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein,
interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-
selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide,
were measured before and after 2 months of treatment with a mandibular
advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the
Apnoea–Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers
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